DK0670713T3 - Farmaceutisk formulering - Google Patents

Farmaceutisk formulering

Info

Publication number
DK0670713T3
DK0670713T3 DK94901148T DK94901148T DK0670713T3 DK 0670713 T3 DK0670713 T3 DK 0670713T3 DK 94901148 T DK94901148 T DK 94901148T DK 94901148 T DK94901148 T DK 94901148T DK 0670713 T3 DK0670713 T3 DK 0670713T3
Authority
DK
Denmark
Prior art keywords
pct
date
pharmaceutical formulation
sec
active agent
Prior art date
Application number
DK94901148T
Other languages
English (en)
Inventor
Christer Nystroem
Lennart Paalzow
Sten-Magnus Aquilonius
Original Assignee
Neopharma Production Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharma Production Ab filed Critical Neopharma Production Ab
Application granted granted Critical
Publication of DK0670713T3 publication Critical patent/DK0670713T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
DK94901148T 1992-11-30 1993-11-29 Farmaceutisk formulering DK0670713T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system
PCT/SE1993/001029 WO1994012153A1 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation

Publications (1)

Publication Number Publication Date
DK0670713T3 true DK0670713T3 (da) 2000-03-20

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94901148T DK0670713T3 (da) 1992-11-30 1993-11-29 Farmaceutisk formulering

Country Status (15)

Country Link
US (1) US5635213A (da)
EP (1) EP0670713B3 (da)
JP (1) JP3661703B2 (da)
AT (1) ATE184191T3 (da)
AU (1) AU688290B2 (da)
CA (1) CA2150464C (da)
DE (2) DE69326350T3 (da)
DK (1) DK0670713T3 (da)
ES (1) ES2137350T7 (da)
FR (1) FR04C0024I2 (da)
GR (1) GR3031988T3 (da)
NL (1) NL300169I1 (da)
NZ (1) NZ258276A (da)
SE (1) SE9203594D0 (da)
WO (1) WO1994012153A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
UA95954C2 (ru) * 2006-05-31 2011-09-26 Солвей Фармасьютикалс Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2653179B1 (en) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System for calculating and administering a drug to a patient with Parkinson's disease
EP4356907A1 (en) 2014-09-04 2024-04-24 LobSor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
PT3209302T (pt) 2014-10-21 2019-07-19 Abbvie Inc Profármacos de carbidopa e l-dopa e a sua utilização para tratar doença de parkinson
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018017850A1 (en) * 2016-07-20 2018-01-25 Abbvie Inc. Levodopa and carbidopa intestinal gel and methods of use
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
AU2019237857A1 (en) 2018-03-23 2020-10-08 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2714065A1 (de) * 1977-03-30 1978-10-12 Boehringer Mannheim Gmbh Instillationszubereitung
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Also Published As

Publication number Publication date
ATE184191T3 (de) 1999-09-15
FR04C0024I2 (da) 2010-12-31
DE69326350D1 (de) 1999-10-14
NL300169I1 (nl) 2005-03-01
NZ258276A (en) 1996-09-25
US5635213A (en) 1997-06-03
ES2137350T7 (es) 2017-11-13
DE122005000021I1 (de) 2006-02-23
DE69326350T3 (de) 2018-01-11
AU688290B2 (en) 1998-03-12
FR04C0024I1 (da) 2004-03-12
JP3661703B2 (ja) 2005-06-22
CA2150464A1 (en) 1994-06-09
DE69326350T2 (de) 2000-01-27
EP0670713B1 (en) 1999-09-08
GR3031988T3 (en) 2000-03-31
EP0670713B3 (en) 2016-10-05
CA2150464C (en) 2002-02-05
ES2137350T3 (es) 1999-12-16
JPH08504764A (ja) 1996-05-21
AU5583694A (en) 1994-06-22
WO1994012153A1 (en) 1994-06-09
SE9203594D0 (sv) 1992-11-30
EP0670713A1 (en) 1995-09-13

Similar Documents

Publication Publication Date Title
DK0670713T3 (da) Farmaceutisk formulering
ES2115945T3 (es) Preparaciones topicas cosmeticas y medicinales.
DE69305328T2 (de) Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus
FI953442A (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
ES2091012T3 (es) Preparacion y utilizacion de nuevos sistemas coloidales dispersables a base de ciclodextrina, en forma de nanoesferas.
ATE162725T1 (de) Verbesserte hautpenetrationssysteme fuer erhoehte topische freisetzung von arzneimitteln
MX9304530A (es) Suministro topico mejorado de farmacos.
MY101791A (en) New benzimidazole derivatives
TW347339B (en) Oral delivery of discrete units
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
DE69535127D1 (de) Emulgierte arzneistoffabgabesysteme
MX9307256A (es) Dispositivo de administracion que tiene excipientes capsulados.
DE59505047D1 (de) Versprühbare filmbildende wirkstoffabgabesysteme zur anwendung an pflanzen
DE69129696D1 (de) Polymeres arzneimittelabgabesystem
PL268927A1 (en) Method of obtaining novel derivatives of benzimidazole
ATE175867T1 (de) Ophthalmologische zubereitungen
MY102411A (en) Nasal solutions
CA2185883A1 (en) The use of dimeticone as a transport and carrier system and/or drug delivery system
HRP20020332B1 (en) Oral solution containing galanthamine and a sweetening agent
ES2193562T3 (es) Dispositivo de dosificacion.
DK0804152T3 (da) Lactulose-pastiller
MX9302272A (es) Retinoides solubles en agua.
DE59406568D1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel
JO1519B1 (en) New compounds (new benzimidazole derivatives are effective as ulcers)
KR970005289A (ko) 디프사쿠스 사포닌 C(Dipsacus saponin C)를 유효성분으로 함유하는 비마약성 중추성 진통제